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Abstract
Prostate cancer is the second most common cancer diagnosed in men worldwide; however,
few patients are affected by clinically significant disease within their lifetime. Unfortunately,
the means to discriminate between patients with indolent disease and those who progress
to aggressive prostate cancer is currently unavailable, resulting in over-treatment of
patients. We therefore aimed to determine biomarkers of prostate cancer that can be used
in the clinic to aid the diagnosis and prognosis. Immunohistochemistry analysis was carried
out on prostate cancer specimens with a range of Gleason scores. Samples were stained
and analysed for intensity of the Seven Transmembrane Epithelial Antigen of the Prostate
(STEAP)-1, -2, -3, -4 and the Divalent Metal Transporter 1 (DMT1) proteins to determine
suitable biomarkers for classification of patients likely to develop aggressive prostate can-
cer. Additionally, these proteins were also analysed to determine whether any would be able
to predict future relapse using Kaplan Meier analysis. Data generated demonstrated that the
protein expression levels of STEAP2 correlated significantly with Gleason score; further-
more, STEAP4 was a significant predictor of relapse. This data indicates that STEAP2
could be potential prognostic candidate for use in combination with the current prostate can-
cer detection methods and the presence of STEAP4 could be an indicator of possible
relapse.
Introduction
Prostate cancer (PCa) is the second most common cancer worldwide, however there is cur-
rently no successful screening system [1, 2]. Men without symptoms are discouraged from
PCa screening by the US Preventive Services Task Force due to the risk of detecting slow grow-
ing cancers that will not require treatment within the patients’ lifetime [3]. As slow growing
cancers cannot be distinguished from fast growing, aggressive cancers, new prognostic
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biomarkers are required to improve patient stratification, assist with clinical management of
the disease and prevent the overtreatment of PCa patients.
The six-transmembrane epithelial antigen of the prostate (STEAP) family contains four
members (STEAP-1, -2, -3 and -4). Proteins containing this 6-transmembrane domain often
function as ion channels at cell junctions, which could be a function of the STEAP family, in
addition to their suggested metalloreductase function [4]. Due to significant sequence homol-
ogy with various metalloreductases, it has been suggested that the STEAP family may play a
role in iron and copper reduction. Indeed, STEAP2, 3 and 4 expression has been shown to
increase iron and copper uptake and promote reduction of iron and copper in vitro [5]. Before
endocytosed iron can be released from the endosome, into the cell it must be reduced and
STEAP, as a ferrireductase, can reduce Fe3+ to Fe2+ which allows its transport out of the endo-
some by the divalent metal transporter 1 (DMT1). DMT1 has been shown to be overexpressed
in colorectal cancer, consequently dysregulating iron homeostasis, resulting in tumourigenesis
[6, 7].
The STEAP protein family has been implicated in many forms of cancer due to overexpres-
sion in malignant cells when compared to their non-malignant counterparts. STEAP1 was the
first discovered and the smallest member of the STEAP family at only 339 amino acids, as it is
missing the N-terminal FNO-like domain [4]. STEAP1 localises to the plasma membrane, it
mediates the transfer of small molecules between adjacent cells in culture and is involved in
intercellular communication [8, 9]. STEAP1 is expressed in prostate epithelium and at very
low levels in a variety of other epithelial tissues including bladder tissue [10]. However,
STEAP1 is highly overexpressed in PCa along with 10 other cancers including brain, lung and
pancreatic and is associated with poor prognosis and shorter biochemical recurrence survival
[10–12]. STEAP2, also known as STAMP1, is primarily expressed in the prostate, with the
ovary being the only other significant area of expression [13]. STEAP2 has been shown to shut-
tle between the Golgi and the plasma membrane before co-localising with early endosomes
and it has been speculated to be involved in the processing and/or excretion of prostate specific
proteins such as prostate specific antigen (PSA) [14]. The expression of STEAP2 in carcinoma
and Benign Prostatic Hyperplasia (BPH) was compared by Porkka et al, with results showing
that STEAP2 expression was significantly higher in carcinoma than in BPH [13]. STEAP3, also
known as STAMP3 and TSAP6 is shown to be expressed at low levels in all tissues but gener-
ally decreased in cancer [15]. STEAP3 has been shown contain a p53-response element within
the promoter region and to be transcriptionally activated by p53 in response to stress, suggest-
ing a tumour suppressor role of STEAP3, which contrasts the other STEAP proteins [16]. Fur-
thermore, STEAP3 is strongly implicated in iron metabolism and is also reported to be
expressed at important iron metabolism sites such as the bone marrow, foetal liver and macro-
phages, in addition to partially co-localising with transferrin, transferrin receptor and DMT1
all of which are important in the transferrin cycle [17, 18]. This therefore advocates another
important role for STEAP3 within iron metabolism. STEAP 4, also known as STAMP2 and
TIARP, is primarily expressed in the heart, lung, placenta and prostate with virtually no
expression in neuronal tissue [15, 19]. STEAP4 has similar localisation to STEAP2, in addition
to localising to the vesicular-tubular structures and co-localising with early endosome antigen
1 (EEA1), suggesting a comparable secretory function to STEAP2 [19]. Silencing of STEAP4
resulted in impairment of insulin-stimulated glucose transport and STEAP4 plays a major role
in the protection of cells against metabolic deregulation and inflammatory processes both in
vitro and in vivo [20–22].
This information taken together has led to the hypothesis that the STEAP family, along
with DMT1, may be able to identify the extent of disease and therefore aid the prognosis of
PCa patients, resulting in the administration of more suitable treatments on a patient by
Immunohistochemical analysis of the STEAP protein family
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patient basis. The aim of this study was to determine the differences between protein concen-
tration and localisation of each member of the STEAP family, plus DMT1 and observe whether
any of these proteins could be utilised in a prognostic fashion in the clinic. We present data
here to indicate that STEAP2 may be utilised as a prognostic biomarker, in combination with
current methods, due to the significant correlation of STEAP2 expression and Gleason score.
Materials and methods
Tissue Microarrays (TMAs) were constructed from PCa specimens, from prostatectomy
patients, with a range of Gleason scores (n = 209 malignant and n = 47 patient-matched
healthy samples) (Wales Cancer Bank (WCB), Cardiff, UK). The Wales Cancer Bank is
licensed by the Human Tissue Authority (licence 12107) to store human tissue for research,
which has been obtained from patients providing informed consent. Wales Cancer Bank holds
ethical approval from Wales Research Ethics Committee 3 to act as a research tissue biobank
to both collect and issue biomaterials for cancer related research, where successful peer-
reviewed applications have been approved. All methods applied in this report were therefore
carried out in accordance with relevant guidelines and regulations in place for Wales Cancer
Bank related studies. Prostate samples were bordered and crossed with colorectal tumour tis-
sue to aid orientation. Hematoxylin and eosin (H&E) stained TMA slides were objectively ana-
lysed by an independent pathologist to determine that the samples were of a satisfactory
standard. Samples with insufficient staining, poor quality of stain, compromised cores (e.g.
rolled/partially missing) or lack of tumour cells in the sample were discarded from analysis.
Patient information was collected and stored in an anonymised fashion, including Gleason
score, PSA levels, age, TNM classification, death and relapse (Table 1).
The TMA slides were processed using the Benchmark XT automated staining system
(ULTRA Ventana, Singleton Hospital, Swansea, UK). Formalin fixed, paraffin embedded sec-
tions mounted on FLEX IHC slides were baked in a 60˚ oven for 1 hour. Barcode labelled
slides were placed on the Ventana machine, rinsed with reaction buffer and a liquid cover slip
was applied before Ezprep solution was used to dewax the slides at 72˚. Following antigen-
retrieval, pre-peroxidase inhibitor was applied for 4 minutes at 36˚. Antigen retrieval condi-
tions and antibody incubation conditions for each antibody utilised are described in Table 2.
OV HQ Universal linker containing secondary antibody was applied (8mins), OV- HPR mul-
timer was applied (8mins). OV DAB and H2O2 was applied (8mins) before being incubated in
copper (4mins) followed by OV AMP multimer (4-8mins). The slides were then counter-
stained with Heamatoxylin for 8 mins.
Samples were scored by two individuals, blind to patient details, based on the intensity
(0 = Negative, 1 = Weak, 2 = Moderate and 3 = strong) of the highest stain observed and the
Table 1. Patient Information.
Gleason Score STEAP1 STEAP2 STEAP3 STEAP4 DMT1 Age Range PSA Range Death/ Relapse
Normal 24 28 27 25 27 48–75 2.8–19.6 4
6 24 22 23 23 26 49–71 2.2–19.6 3
3+4 = 7 40 36 37 40 39 49–74 4.5–22.5 2
4+3 = 7 12 12 11 12 12 54–75 2.2–18 3
8 23 24 24 24 27 48–72 3.1–31.7 9
9/10 46 46 48 47 45 43–84 2.2–160 9
Total 169 168 170 171 176 43–84 2.2–160 30
Number of samples available for each biomarker, along with age range, PSA range and number of death and relapse cases for each Gleason score.
https://doi.org/10.1371/journal.pone.0220456.t001
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percentage (0 = 0%, 1 = 1–25%, 2 = 25–50%, 3 = 51–75% and 4 = 75–100%) of cells stained
with this intensity, subcellular localisation was also noted. The final score was then obtained
by multiplying the intensity and percentage scores together; defined as: 0 = Negative, 1–3 =
Weak, 4–6 = Moderate and 8–12 = Strong [23, 24].
Statistical analysis
Statistical analysis was performed using SPSS software version 22. Pearson test to assess the
correlation between biomarker, Gleason, PSA and age. Differences between means (two sam-
ples) were analysed using the independent samples t-test and >two samples were analysed a
one-way ANOVA. A p-value of<0.05 was significant. Kaplan Meier plots were carried out to
determine if there was a significant difference in the time taken to relapse. Kaplan Meier analy-
sis was performed using SPSS and the long rank test was utilised to analyse this data. Due to
requirement for normally distributed data PSA values were log transformed to produce a nor-
mal distribution.
Results
The protein expression of the STEAP family, along with DMT1 were analysed in PCa samples
with varying Gleason scores using IHC. In addition to the Gleason score of the patient samples,
PSA level, age and relapse information was provided as stated in Table 1. Comparisons between
each potential biomarker and the patient information were carried out to observe the relation-
ship between current prognostic methods and identification of aggressive PCa. This evaluation
was aimed at determining whether additional prognostic information required for successful
clinical management of PCa patients could be fulfilled by evaluation the STEAP protein family.
STEAP2 protein expression significantly correlates with Gleason score
The protein concentration and localisation of each biomarker was observed and compared to
Gleason score (Figs 1 and 2). STEAP1 expression was significantly higher in the PCa speci-
mens relative to the normal prostate specimens (p<0.001) and was observed to localise to the
cytoplasm of all cells. The STEAP1 stain intensity in the normal samples was weak, the staining
increased slightly in the Gleason 6 samples and then dramatically in the Gleason 7 (3+4 and
4+3) onwards.
STEAP2 expression was significantly higher level in the PCa specimens relative to the nor-
mal prostate specimens (p<0.001) with a positive correlation between STEAP2 and Gleason
score (r = 0.308, p<0.001). STEAP2 expression was very low in the normal prostate specimens
with only minimal staining present in the cytoplasm. In contrast to this, STEAP2 was observed
Table 2. Antibodies and hybridisation conditions utilised in the IHC analysis.
Retrieval Conditions Antibody Conditions
Antibody Supplier Positive Control Buffer Time (mins) Dilution Temperature Incubation Time (mins)
STEAP1 Abcam Kidney and prostate CC1 8 1:200 RT 24
STEAP2 Abcam Prostate CC1 32 1:50 36 28
STEAP3 Abcam Pancreas and prostate CC1 32 1:80 RT 24
STEAP4 Abcam Skin and Prostate CC1 40 1:50 RT 40
DMT1 Abcam Kidney and Prostate CC1 40 1:100 36 40
The dilution, temperature and incubation time were optimised for each antibody using the positive controls specified; the final conditions are detailed here. (Cell
Conditioning 1 Buffer = CC1 and Room Temperature = RT). Corresponding images of the positive control tissue can be found in S1 Fig.
https://doi.org/10.1371/journal.pone.0220456.t002
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to localise to the nucleus in the PCa specimens. Stain intensity was increased dramatically in
the Gleason 6 samples. From Gleason 7 (3+4 and 4+3) the intensity of STEAP2 stain increased
in a step wise fashion to Gleason 9/10.
Fig 1. Alterations in biomarker protein expression compared against Gleason score. Panel shows the differences in
protein expression of the 4 STEAP family members plus DMT1 with regards to increasing Gleason score. (A) STEAP1
expression increases from the normal sample to the cancer samples and increases from Gleason 6 to Gleason 7. From
Gleason 7, the protein expression appears to decrease in a step-wise manner towards Gleason 9/10. (B) STEAP2
expression increases from the normal samples to the cancer samples, and then continues to increase in a step-wise
manner towards Gleason 9/10. (C) STEAP3 protein expression is consistently high in all samples observed. (D)
STEAP4 protein expression increases from the normal to cancer samples and remains high. The highest protein
expression is observed in the Gleason 7 samples. (E) DMT1 protein expression increases from the normal to cancer
samples, then remains consistently high throughout. Scale bars represent 50 μm (main image) and 20 μm (insert).
https://doi.org/10.1371/journal.pone.0220456.g001
Fig 2. Correlation between biomarker and Gleason score. Bars show Healthy patients against Gleason score
breakdown. STEAP1, 2, 4 and DMT1 protein expression was significantly increased in PCa samples compared to
healthy samples. Significant positive correlation (r = 0.308, p<0.001) was observed for STEAP2 against Gleason scores.
Significance between healthy vs cancer samples (independent samples, two-tailed t-test) denoted as �<0.05, ��<0.01,
���<0.001.
https://doi.org/10.1371/journal.pone.0220456.g002
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STEAP3 expression was high in all samples and present at the cell membranes and the cyto-
plasm, with no difference between healthy and cancer samples and no correlation with regards
to Gleason score.
STEAP4 expression was very low in the normal prostate specimens with only minimal pro-
tein expression present in the cytoplasm. In contrast, STEAP4 localises to the lumen, with
heavy cytoplasmic staining in all cells of the PCa specimens. STEAP4 expression was signifi-
cantly higher in the PCa specimens relative to the normal prostate specimens (p<0.001),
although there was no correlation between STEAP4 and Gleason scores.
DMT1 expression was very low in the normal prostate specimens, present only in the cyto-
plasm. In contrast, DMT1 protein expression is dramatically increased and is observed to
localise to the cytoplasm of all PCa specimens. DMT1 expression was significantly higher
level in the PCa specimens when compared to the normal prostate specimens (p<0.001). No
correlation was observed between DMT1 and Gleason score, according to Pearson correlation
tests.
No correlation between LogPSA/Age and biomarker score
The two common factors in the progression of PCa are PSA value and age. As Gleason score
increases, we have observed that the PSA value and the age of the patient also increase
(r = 0.217, p = 0.011 and 0.193, p = 0.023 respectively) (Fig 3A and 3B), which indicates that
these two factors can predict the Gleason score of the patient. However, as shown in Fig 3C,
PSA value and age are also significantly positively correlated (0.231, p = 0.006), indicating that
there may be other factors influencing the increase of PSA in the body. For a biomarker to be
capable of predicting prognostic outcome, it is important that it is not affected by any other
confounding factor. In the present study, biomarker score was split into three groups: Low (0–
2), Medium (3–6) and High (8–12) and we found no correlation with either PSA value or age
for any of the biomarkers analysed (Fig 3D and 3E).
Fig 3. Correlations of PSA Value, Age, Gleason score and biomarker score. Both (A) LogPSA value and (B) Age
correlate positively with Gleason score (r = 0.217, p = 0.011 and 0.193, p = 0.023 respectively, Pearson test). (C) A
positive correlation was also observed between LogPSA and age (r = 0.231, p = 0.006, Pearson test). No correlation was
observed between STEAP1, 2, 3, 4 or DMT1 with (D) PSA value or (E) Age. Significance denoted as �<0.05, ��<0.01,
���<0.001.
https://doi.org/10.1371/journal.pone.0220456.g003
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Chance of relapse was predicted by Gleason score, PSA value and age, while
time taken to relapse was predicted by STEAP4 expression
It is important for a prognostic biomarker to be able to determine the likely progression of the
disease. Fig 4A shows a positive correlation between increasing Gleason score and relapsing
population (r = 0.8). Fig 4B and 4C show that patients with increasing PSA levels and age were
more likely to suffer from death and relapse, however, this was not significant. Fig 4D and 4E
indicate that relapse was more likely to occur in patients with increased DMT1 expression
(p = 0.037, independent samples, two-tailed t-test). A binary logistic regression was carried out
to determine the true prognostic value of DMT1, this analysis showed the odds of relapse
increased by 20.8% per unit increase of DMT1 (p = 0.037). This increases to 22.7% per unit of
DMT1 score (p = 0.028) when controlling for Gleason, PSA and Age. This therefore indicates
that the prognostic value of DMT1 stands true when controlling for the other variable, namely
Gleason score, PSA value and age. Fig 4E illustrates the increase of relapse cases with respect to
DMT1 score, where score was split into three groups: Low (0–2), Medium (3–6) and High (8–
12). No Significant difference was observed in any STEAP biomarker expression with regards
to relapse (Fig 4D).
Kaplan Meier graphs were used to evaluate the relationship between the test biomarker
expression and time to relapse, we observed no significant association for Gleason, STEAP1,
STEAP2, STEAP3 and DMT1 scores (Fig 5A, 5B, 5C, 5D and 5F). In contrast, STEAP4 was the
only biomarker showing significant association with relapse suggesting that patients with a
high STEAP4 protein expression relapsed more quickly than those with medium or low
STEAP4 protein expressions (Fig 5E).
Discussion
Currently, Gleason scoring is the gold standard for predicting PCa outcome; however, the
Gleason score is subjective, being dependent on the pathologist’s judgement. It is therefore
important that additional biomarkers are identified that are more predictive of patients likely
to develop advanced disease. In the present study, all members of the STEAP protein family
Fig 4. Chance of relapse was increased with increasing Gleason Score, PSA level and age. (A) Gleason, (B) PSA level
and (C) Age were plotted against the death and relapse of the patient. There was a positive correlation between
increasing Gleason score and relapsing patients. (D) Relapse was significantly more likely with a higher DMT1 score
(p = 0.037, independent samples, two-tailed t-test) and (E) An increased number of relapse cases occur with a higher
DMT1 score. (High group n = 13, medium group n = 4, low group n = 0). Significance denoted as �<0.05, ��<0.01 and
���<0.001.
https://doi.org/10.1371/journal.pone.0220456.g004
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were analysed to determine their suitability to improve the prognostic prediction of PCa. In
addition to the analysis of STEAP1-4, DMT1, was also analysed. There are significant positive
correlations between each of Gleason, PSA and age indicating they may be closely related.
These observations are supported by the literature, where correlations between these parame-
ters have previously been established [25–27]. In particular, the increase of PSA level with age
is widely documented and has resulted in the introduction of age-specific PSA reference
ranges in an attempt to increase the accuracy of PSA testing [28]. Differing PSA levels have
also been linked to race, with some studies suggesting not only age-specific, but race-specific
PSA ranges for the detection of PCa [29]. This information presents a poor case for PSA as a
diagnostic tool as there are multiple factors not related to tumourigenesis that influence PSA
level.
In the present IHC study, each biomarker protein expression score was correlated to Glea-
son score and these results indicated a significant positive correlation between STEAP2 and
Gleason score. This finding contradicts one previous study that reported no significant
Fig 5. Kaplan Meier curve as a function of Gleason score, STEAP1, 2, 3, 4 and DMT1 Score. (A) Patients with
higher Gleason scores are more likely to progress to relapse than those with lower Gleason scores, although there is no
significant difference in time taken to progress to relapse between all Gleason scores. (B) Patients with higher STEAP1
score are more likely to progress to relapse than those with medium and low scores, however, there was no significant
difference. (High group n = 17, medium group n = 10 and low group n = 7) (C) Patients with higher STEAP2 score are
more likely to progress to relapse than those with medium and low scores, however, there was no significant difference.
(High group n = 6, medium group n = 21 and low group n = 6) (D) Patients with lower STEAP3 score are less likely to
progress to relapse than those with medium and high scores, however this was not significant. (High group n = 18,
medium group n = 11 and low group n = 1) (E) Patients with higher STEAP4 score were significantly more likely to
progress to relapse earlier than those with medium or low scores (p = 0.025, long rank test). (High group n = 2,
medium group n = 18 and low group n = 10) (F) There was no difference in time taken to relapse between high and
medium DMT1 scores. (High group n = 27 and medium group n = 8).
https://doi.org/10.1371/journal.pone.0220456.g005
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association between STEAP2 and Gleason score [30]. However, the sample size used by the
Wang et al study (n = 67) was approximately half the samples used the present study and so
possibly lacking in power.
Since Gleason, PSA and age are all closely interlinked and elevated STEAP2 protein expres-
sion levels are significantly correlated with increasing Gleason score, it was important to deter-
mine whether the protein expression of STEAP-1-, -2, -3, -4 and DMT1 were correlated to
PSA level and age. A biomarker capable of predicting prognostic outcome that was not affected
by other factors would be beneficial. No correlation was found between any STEAP biomarker
and PSA and age respectively supporting the suitability of STEAP2 as a prognostic test for
aggressive PCa.
Although, STEAP4 was the only biomarker to be significantly associated with patient
relapse it was notable that the number of relapsing patients was very small (n = 36 out of 185
patients). These results therefore would benefit from being validated with a larger patient
cohort.
In conclusion, we suggest that STEAP1, 2, 4 and DMT1 are suitable candidates to distin-
guish patients with cancer from those that have no tumour present. When the correlation with
Gleason score was taken into consideration, STEAP2 presents as a potential prognostic bio-
marker, although on its own, it is not a solid indicator of the extent of disease. We therefore
propose STEAP2 to be used in combination with existing PCa screening methods, (e.g. PSA
testing, DRE examination and biopsy analysis). Although studies with larger cohorts of
patients are required, this biomarker is particularly promising as a predictor of prognostic out-
come due to the lack of association with confounders such as PSA levels and age.
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S1 Fig. Immunohistochemistry positive control tissue staining for STEAP1-4 and DMT1.
Kidney and prostate tissues were used as positive controls for STEAP1 and DMT1 IHC, pros-
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